Lobbying disclosures · Lobbying report
CRL: second_quarter 2026 lobbying report
Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues related to preclinical testing safety assessments, including New Approach Methodologies and virtual control groups Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues surrounding improvements to clinical research capabilities and modernization of research methods.
Follow CRL- Became public
- Jul 20, 2026, 10:36 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 4:21 PM EST
Why this is connected
Exact legal-name match: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (https://www.sec.gov/Archives/edgar/data/1100682/).
Reported lobbying amounts
Income: $70,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/c1cdca46-ed9c-4c57-b769-06dd2c34c3ad/","filing_uuid":"c1cdca46-ed9c-4c57-b769-06dd2c34c3ad","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/c1cdca46-ed9c-4c57-b769-06dd2c34c3ad/print/","filing_document_content_type":"text/html","income":"70000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Tazeen Ahmad","dt_posted":"2026-07-20T22:36:01-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"926 Pennsylvania Ave, SE","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20003","registrant":{"id":72053,"url":"https://lda.gov/api/v1/registrants/72053/","house_registrant_id":35843,"name":"CAPITOL HILL CONSULTING GROUP","description":"Government Relations Firm","address_1":"926 Pennsylvania Ave, SE","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20003","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"TAZEEN AHMAD","contact_telephone":"+1 202-488-0101","dt_updated":"2026-08-17T10:56:59.984637-04:00"},"client":{"id":71107,"url":"https://lda.gov/api/v1/clients/71107/","client_id":71107,"name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC","general_description":"Contract Research Organization","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-01-09"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues related to preclinical testing safety assessments, including New Approach Methodologies and virtual control groups","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":61615,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"SUTTER","suffix":null,"suffix_display":null},"covered_position":"Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02","new":false},{"lobbyist":{"id":141629,"prefix":"mr","prefix_display":"MR.","first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"DAVIS","suffix":null,"suffix_display":null},"covered_position":"Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011).","new":false},{"lobbyist":{"id":71228,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":"ELIZABETH","last_name":"WILKINSON-HOLLAND","suffix":null,"suffix_display":null},"covered_position":"Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19).","new":false},{"lobbyist":{"id":150427,"prefix":null,"prefix_display":null,"first_name":"KIMBERLEE","nickname":null,"middle_name":null,"last_name":"TRZECIAK","suffix":null,"suffix_display":null},"covered_position":"FDA. Dep. Commissioner; 8/23-1/25. Assoc. Commissioner Leg. Affairs; 2/2022-08/2023. House Com. Energy & Commerce: Chief Health Advisor, 2/22-4/19. Sen. Health Policy Advisor, 3/19-3/15. Rep. John D. Dingell - LD, 05/13-07/11. Sen. LA, 7/11-08/09, LA","new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOO","general_issue_code_display":"Food Industry (safety, labeling, etc.)","description":"Issues surrounding improvements to clinical research capabilities and modernization of research methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":61615,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"SUTTER","suffix":null,"suffix_display":null},"covered_position":"Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02","new":false},{"lobbyist":{"id":141629,"prefix":"mr","prefix_display":"MR.","first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"DAVIS","suffix":null,"suffix_display":null},"covered_position":"Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011).","new":false},{"lobbyist":{"id":71228,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":"ELIZABETH","last_name":"WILKINSON-HOLLAND","suffix":null,"suffix_display":null},"covered_position":"Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19).","new":false},{"lobbyist":{"id":150427,"prefix":null,"prefix_display":null,"first_name":"KIMBERLEE","nickname":null,"middle_name":null,"last_name":"TRZECIAK","suffix":null,"suffix_display":null},"covered_position":"FDA. Dep. Commissioner; 8/23-1/25. Assoc. Commissioner Leg. Affairs; 2/2022-08/2023. House Com. Energy & Commerce: Chief Health Advisor, 2/22-4/19. Sen. Health Policy Advisor, 3/19-3/15. Rep. John D. Dingell - LD, 05/13-07/11. Sen. LA, 7/11-08/09, LA","new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues surrounding improvements to clinical research capabilities and modernization of research methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":61615,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"SUTTER","suffix":null,"suffix_display":null},"covered_position":"Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02","new":false},{"lobbyist":{"id":141629,"prefix":"mr","prefix_display":"MR.","first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"DAVIS","suffix":null,"suffix_display":null},"covered_position":"Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011).","new":false},{"lobbyist":{"id":71228,"prefix":null,"prefix_display":null,"first_name":"EMILY","nickname":null,"middle_name":"ELIZABETH","last_name":"WILKINSON-HOLLAND","suffix":null,"suffix_display":null},"covered_position":"Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19).","new":false},{"lobbyist":{"id":150427,"prefix":null,"prefix_display":null,"first_name":"KIMBERLEE","nickname":null,"middle_name":null,"last_name":"TRZECIAK","suffix":null,"suffix_display":null},"covered_position":"FDA. Dep. Commissioner; 8/23-1/25. Assoc. Commissioner Leg. Affairs; 2/2022-08/2023. House Com. Energy & Commerce: Chief Health Advisor, 2/22-4/19. Sen. Health Policy Advisor, 3/19-3/15. Rep. John D. Dingell - LD, 05/13-07/11. Sen. LA, 7/11-08/09, LA","new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in CRL
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
Sold Charles River Laboratories International CRL
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
Bought Charles River Laboratories International CRL
$15K–$50K · Traded May 8, 2025 · disclosed Jun 22, 2025
- May 31, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
Sold Charles River Laboratories International CRL
$1K–$15K · Traded May 15, 2025 · disclosed May 31, 2025
- May 8, 2025$15K–$50K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
Bought Charles River Laboratories International CRL
$15K–$50K · Traded Apr 8, 2025 · disclosed May 8, 2025
- Feb 12, 2025$1K–$15K
Rep. Julie Johnson (D-TX-32)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Dec 5, 2024$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Nov 15, 2024 · disclosed Dec 5, 2024
- Nov 8, 2023$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Oct 2, 2023 · disclosed Nov 8, 2023
- Oct 10, 2023$1K–$15K
Rep. Lois Frankel (D-FL-22)
Sold Charles River Laboratories International CRL
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.